Pay in 4 interest-free payments of $6.43 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Recently, PBMs have created drug manufacturing subsidiaries, raising additional conflict-of-interest concerns
This marks the first time a GLP-1 drug gained a formal heart-health indication, underscoring that GLP-1 therapies now address both metabolic and cardiovascular disease
1 Capsule microcrystalline cellulose, silicon dioxide
This work was supported by the National Natural Science Foundation of China (grant numbers 82200699 to XC, and 82273560 to LJ), the Yunnan Provincial Science and Technology Program (grant number 202502AS100004 to XW), and the Ningbo City Public Welfare Research Plan Project (grant number 2024S038 to LJ)
PubMed indexes the published retatrutide trial data
US$ 24.35
US$ 27.93
US$ 26.25
US$ 24.87
